Hepatically-metabolized and -excreted artificial oxygen carrier, hemoglobin vesicles, can be safely used under conditions of hepatic impairment

Toxicology and Applied Pharmacology

Volumn 248, Issue 3, 2010, Pages 234-241

  Taguchi, Kazuaki ^a   Miyasato, Mayumi ^a   Ujihira, Hayato ^a   Watanabe, Hiroshi ^a   Kadowaki, Daisuke ^a   Sakai, Hiromi ^b   Tsuchida, Eishun ^b   Horinouchi, Hirohisa ^c   Kobayashi, Koichi ^c   Maruyama, Toru ^a   Otagiri, Masaki ^a,d  

^a KUMAMOTO UNIVERSITY   (Japan)

^b WASEDA UNIVERSITY   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d SOJO UNIVERSITY   (Japan)

Author keywords

Artificial oxygen carrier; Chronic cirrhosis; Hemoglobin vesicle; Safety and toxicology evaluations

Indexed keywords

BILIRUBIN; CARBON TETRACHLORIDE; HEMOGLOBIN; HEMOGLOBIN VESICLE; HEMOSIDERIN; LIPOSOME; RECOMBINANT HUMAN SERUM ALBUMIN; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; BLOOD SUBSTITUTE; OXYGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; HISTOPATHOLOGY; LIPID VESICLE; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER METABOLISM; MONONUCLEAR PHAGOCYTE; NONHUMAN; OSMOTIC PRESSURE; OXIDATIVE STRESS; RAT; SPLEEN; SUSPENSION; ANIMAL; COMPARATIVE STUDY; DRUG-INDUCED LIVER INJURY, CHRONIC; HUMAN; INTOXICATION; MALE; METABOLISM; RANDOMIZATION; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD SUBSTITUTES; CARBON TETRACHLORIDE POISONING; DRUG-INDUCED LIVER INJURY, CHRONIC; HEMOGLOBINS; HUMANS; LIPOSOMES; MALE; OXYGEN; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 77957226817     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2010.08.006     Document Type: Article

References (35)

1. Abe H., Ikebuchi K., Hirayama J., Fujihara M., Takeoka S., Sakai H., Tsuchida E., Ikeda H. Virus inactivation in hemoglobin solution by heat treatment. Artif. Cells Blood Substit. Immobil. Biotechnol. 2001, 29:381-388.
2. Abe H., Fujihara M., Azuma H., Ikeda H., Ikebuchi K., Takeoka S., Tsuchida E., Harashima H. Interaction of hemoglobin vesicles, a cellular-type artificial oxygen carrier, with human plasma: effects on coagulation, kallikrein-kinin, and complement systems. Artif. Cells Blood Substit. Immobil. Biotechnol. 2006, 34:1-10.
3. Abe H., Azuma H., Yamaguchi M., Fujihara M., Ikeda H., Sakai H., Takeoka S., Tsuchida E. Effects of hemoglobin vesicles, a liposomal artificial oxygen carrier, on hematological responses, complement and anaphylactic reactions in rats. Artif. Cells Blood Substit. Immobil. Biotechnol. 2007, 35:157-172.
4. Arnaud F., Hammett M., Philbin N., Scultetus A., McCarron R., Freilich D. Hematologic effects of recombinant factor VIIa combined with hemoglobin-based oxygen carrier-201 for prehospital resuscitation of swine with severe uncontrolled hemorrhage due to liver injury. Blood Coagul. Fibrinolysis 2008, 19:669-677.
5. Balla J., Vercellotti G.M., Jeney V., Yachie A., Varga Z., Eaton J.W., Balla G. Heme, heme oxygenase and ferritin in vascular endothelial cell injury. Mol. Nutr. Food Res. 2005, 49:1030-1043.
6. Braggins P.E., Trakshel G.M., Kutty R.K., Maines M.D. Characterization of two heme oxygenase isoforms in rat spleen: comparison with the hematin-induced and constitutive isoforms of the liver. Biochem. Biophys. Res. Commun. 1986, 141:528-533.
7. Burhop K., Gordon D., Estep T. Review of hemoglobin-induced myocardial lesions. Artif. Cells Blood Substit. Immobil. Biotechnol. 2004, 32:353-374.
8. Cabrales P., Sakai H., Tsai A.G., Takeoka S., Tsuchida E., Intaglietta M. Oxygen transport by low and normal oxygen affinity hemoglobin vesicles in extreme hemodilution. Am. J. Physiol. Heart Circ. Physiol. 2005, 288:H1885-H1892.
9. Grady J.K., Chen Y., Chasteen N.D., Harris D.C. Hydroxyl radical production during oxidative deposition of iron in ferritin. J. Biol. Chem. 1989, 264:20224-20229.
10. Greenfield R.A., Gerber A.U., Craig W.A. Pharmacokinetics of cefoperazone in patients with normal and impaired hepatic and renal function. Rev. Infect. Dis. 1983, 5(Suppl 1):S127-S136.
11. Grone E.F., Grone H.J. Does hyperlipidemia injure the kidney?. Nat. Clin. Pract. Nephrol. 2008, 4:424-425.
12. Hofbauer B., Friess H., Weber A., Baczako K., Kisling P., Schilling M., Uhl W., Dervenis C., Buchler M.W. Hyperlipaemia intensifies the course of acute oedematous and acute necrotising pancreatitis in the rat. Gut 1996, 38:753-758.
13. Lenz G., Junger H., Schneider M., Kothe N., Lissner R., Prince A.M. Elimination of pyridoxylated polyhemoglobin after partial exchange transfusion in chimpanzees. Artif. Cells Blood Substit. Immobil. Biotechnol. 1991, 19:699-708.
14. Natanson C., Kern S.J., Lurie P., Banks S.M., Wolfe S.M. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. J. Am. Med. Ass. 2008, 299:2304-2312.
15. Nose Y. Is there a role for blood substitutes in civilian medicine: a drug for emergency shock cases?. Artif. Organs 2004, 28:807-812.
16. O'Connell M.J., Peters T.J. Ferritin and haemosiderin in free radical generation, lipid peroxidation and protein damage. Chem. Phys. Lipids 1987, 45:241-249.
17. Okumura H., Katoh M., Minami K., Nakajima M., Yokoi T. Change of drug excretory pathway by CCl4-induced liver dysfunction in rat. Biochem. Pharmacol. 2007, 74:488-495.
18. Ortiz M.C., Fortepiani L.A., de Rycker M., Atucha N.M., Romero J.C., Garcia-Estan J. Pressor and renal effects of cross-linked hemoglobin in anesthetized cirrhotic rats. J. Hepatol. 2000, 32:32-37.
19. Parry E. Blood Substitute: Preparation, Phisiology and Medical Applications 1988.
20. Sakai H., Takeoka S., Park S.I., Kose T., Nishide H., Izumi Y., Yoshizu A., Kobayashi K., Tsuchida E. Surface modification of hemoglobin vesicles with poly(ethylene glycol) and effects on aggregation, viscosity, and blood flow during 90% exchange transfusion in anesthetized rats. Bioconjug. Chem. 1997, 8:23-30.
21. Sakai H., Tomiyama K.I., Sou K., Takeoka S., Tsuchida E. Poly(ethylene glycol)-conjugation and deoxygenation enable long-term preservation of hemoglobin-vesicles as oxygen carriers in a liquid state. Bioconjug. Chem. 2000, 11:425-432.
22. Sakai H., Horinouchi H., Tomiyama K., Ikeda E., Takeoka S., Kobayashi K., Tsuchida E. Hemoglobin-vesicles as oxygen carriers: influence on phagocytic activity and histopathological changes in reticuloendothelial system. Am. J. Pathol. 2001, 159:1079-1088.
23. Sakai H., Tomiyama K., Masada Y., Takeoka S., Horinouchi H., Kobayashi K., Tsuchida E. Pretreatment of serum containing hemoglobin vesicles (oxygen carriers) to prevent their interference in laboratory tests. Clin. Chem. Lab. Med. 2003, 41:222-231.
24. Sakai H., Horinouchi H., Masada Y., Takeoka S., Ikeda E., Takaori M., Kobayashi K., Tsuchida E. Metabolism of hemoglobin-vesicles (artificial oxygen carriers) and their influence on organ functions in a rat model. Biomaterials 2004, 25:4317-4325.
25. Sakai H., Masada Y., Horinouchi H., Ikeda E., Sou K., Takeoka S., Suematsu M., Takaori M., Kobayashi K., Tsuchida E. Physiological capacity of the reticuloendothelial system for the degradation of hemoglobin vesicles (artificial oxygen carriers) after massive intravenous doses by daily repeated infusions for 14days. J. Pharmacol. Exp. Ther. 2004, 311:874-884.
26. Sakai H., Masada Y., Horinouchi H., Yamamoto M., Ikeda E., Takeoka S., Kobayashi K., Tsuchida E. Hemoglobin-vesicles suspended in recombinant human serum albumin for resuscitation from hemorrhagic shock in anesthetized rats. Crit. Care Med. 2004, 32:539-545.
27. Sakai H., Seishi Y., Obata Y., Takeoka S., Horinouichi H., Tsuchida E., Kobayashi K. Fluid resuscitation with artificial oxygen carriers in hemorrhaged rats: profiles of hemoglobin-vesicle degradation and hematopoiesis for 14days. Shock 2009, 31:192-200.
28. Selden C., Owen M., Hopkins J.M., Peters T.J. Studies on the concentration and intracellular localization of iron proteins in liver biopsy specimens from patients with iron overload with special reference to their role in lysosomal disruption. Br. J. Haematol. 1980, 44:593-603.
29. Stuecklin-Utsch A., Hasan C., Bode U., Fleischhack G. Pancreatic toxicity after liposomal amphotericin B. Mycoses 2002, 45:170-173.
30. Taguchi K., Maruyama T., Iwao Y., Sakai H., Kobayashi K., Horinouchi H., Tsuchida E., Kai T., Otagiri M. Pharmacokinetics of single and repeated injection of hemoglobin-vesicles in hemorrhagic shock rat model. J. Control. Release 2009, 136:232-239.
31. Taguchi K., Urata Y., Anraku M., Maruyama T., Watanabe H., Sakai H., Horinouchi H., Kobayashi K., Tsuchida E., Kai T., Otagiri M. Pharmacokinetic study of enclosed hemoglobin and outer lipid component after the administration of hemoglobin vesicles as an artificial oxygen carrier. Drug Metab. Dispos. 2009, 37:1456-1463.
32. Taguchi, K., Miyasato M., Watanabe H., Sakai, H., Tsuchida, E., Horinouchi, H., Kobayashi, K., Maruyama, T., Otagiri, M., 2010. Alteration in the pharmacokinetics of hemoglobin-vesicles in a rat model of chronic liver cirrhosis is associated with Kupffer cell phagocyte activity. J. Pharm. Sci. doi:10.1002/jps.22286.
33. Yamaoka K., Tanigawara Y., Nakagawa T., Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J. Pharmacobiodyn. 1981, 4:879-885.
34. Yu B., Raher M.J., Volpato G.P., Bloch K.D., Ichinose F., Zapol W.M. Inhaled nitric oxide enables artificial blood transfusion without hypertension. Circulation 2008, 117:1982-1990.
35. Zapletal C., Bode A., Lorenz M.W., Gebhard M.M., Golling M. Effects of hemodilution with a hemoglobin-based oxygen carrier (HBOC-201) on ischemia/reperfusion injury in a model of partial warm liver ischemia of the rat. Microvasc. Res. 2009, 78:386-392.